Viralytics kicks off STORM cancer trial
06 March, 2014 by Dylan Bushell-EmblingViralytics (ASX:VLA) has commenced a clinical trial involving delivering multiple intravenous doses of Cavatak to treat late-stage melanoma, prostate, lung and metastatic bladder cancers.
Alchemia licenses CTx cancer drug candidates
06 March, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) will in-license two early-stage cancer drug candidates originating from CTx research.
In-transition Novogen names new directors
05 March, 2014 by Dylan Bushell-EmblingNovogen (ASX:NRT) has named two new directors, including the lead inventor of its new ATM cancer drug platform, and revealed it swung to a 1H14 loss.
Eliminating malaria in the Asia-Pacific
04 March, 2014WEHI joins international partnership to help eliminate malaria.
New theory on type 2 diabetes
04 March, 2014Nobel laureate Dr James D Watson has released a new hypothesis on the causation of type 2 diabetes.
Australia to US Fellowships for 2014
03 March, 2014The 2014 Australia to US Fellowships are open to applications.
Prima signs first licence deal for CVac
25 February, 2014 by Dylan Bushell-EmblingPrima Biomed (ASX:PRR) has finalised a licensing agreement with Israel's Neopharm covering CVac, Prima's treatment candidate under development for ovarian cancer.
CTx gets largest share of CRC funding round
24 February, 2014 by Dylan Bushell-EmblingThe government has allocated $186m for the 16th round of the CRC program, and the Cancer Therapeutics CRC is the top beneficiary.
Alchemia names new CEO, narrows 1H14 loss
24 February, 2014 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has selected COO Thomas Liquard to replace Charles Walker as CEO and announced a slimmer 1H14 net loss of $5.5m.
Prima adds veteran oncologist to advisory board
21 February, 2014 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has appointed leading ovarian cancer researcher Dr Bradley Monk to its scientific advisory board, and revealed it narrowed its 1H14 loss by 26%.
Mesoblast wins key cardiovascular patent in EU
21 February, 2014 by Dylan Bushell-EmblingMesoblast (ASX:MSB) has secured a European patent giving it exclusive rights to use its MPCs and MSCs to treat cardiac and vascular conditions such as heart failure and stroke.
Prana drug shows promise in Huntington's
21 February, 2014 by Dylan Bushell-EmblingPrana Biotechnology's (ASX:PBT) PBT2 candidate improved cognition at the highest dose level during a phase II trial in patients with Huntington's disease.
Funding for medical research
21 February, 2014The latest NHMRC funding round will see $133 million allocated to grant support for medical research.
Potential new approach to treating melanoma
21 February, 2014 by Susan WilliamsonBlocking the delivery of amino acids to melanoma cells may provide another way of tackling this difficult-to-treat disease.
Sirtex 1H14 profit grows 45%
18 February, 2014 by Dylan Bushell-EmblingHigher-dose sales of Sirtex Medical's (ASX:SRX) SIR-Spheres liver cancer treatments and a weaker Australian dollar helped the company grow its revenue and profit for the first half of FY14.
